Acknowledgements:
Author contribution statement: All authors met the criteria for authorship
Financial statement: No financial support was received for the submitted work
Conflict of Interest Statement
MM reports research grants from AstraZeneca, Sanofi, Methapharm Specialty Pharamceuticals and Mirimus, consulting fees from AstraZeneca, Sanofi, Respiplus, GSK, Mirimus. PN reports research grants from AstraZeneca, Teva, Sanofi, Foresee and consulting fees from AstraZeneca, Teva, Sanofi, Equillium, Arrowhead pharma. All other authors have no conflict of interest within the scope of the submitted work.
Table 1: Patient characteristics of severe asthma patients with normalized FeNO low versus raised FeNO after treatment with anti-IL5 biologic.